California State Teachers Retirement System lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 472,118 shares of the medical equipment provider’s stock after selling 46,829 shares during the quarter. California State Teachers Retirement System owned 0.17% of Hologic worth $17,322,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Hall Laurie J Trustee increased its position in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the period. Commonwealth Bank of Australia increased its position in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares during the period. Grove Bank & Trust increased its position in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares during the period. National Asset Management Inc. purchased a new stake in shares of Hologic during the second quarter worth $203,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Hologic during the second quarter worth $213,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Hologic, Inc. (NASDAQ HOLX) opened at $43.44 on Thursday. The company has a market capitalization of $11,989.48, a price-to-earnings ratio of 21.53, a P/E/G ratio of 2.10 and a beta of 0.95. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same quarter in the prior year, the firm posted $0.52 earnings per share. Hologic’s revenue for the quarter was up 10.5% on a year-over-year basis. equities analysts expect that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

In other Hologic news, VP Karleen Marie Oberton sold 1,256 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total value of $49,348.24. Following the completion of the transaction, the vice president now owns 9,406 shares in the company, valued at $369,561.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Insiders sold 28,833 shares of company stock valued at $1,107,270 in the last 90 days. 0.79% of the stock is currently owned by insiders.

A number of analysts have recently weighed in on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Monday, October 2nd. Piper Jaffray Companies reissued a “buy” rating and issued a $48.00 target price on shares of Hologic in a report on Thursday, November 9th. Royal Bank of Canada reissued a “hold” rating and issued a $42.00 target price on shares of Hologic in a report on Friday, September 22nd. Jefferies Group reissued a “buy” rating and issued a $44.00 target price (down previously from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $45.00 target price (down previously from $48.00) on shares of Hologic in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $47.93.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/21/hologic-inc-holx-shares-sold-by-california-state-teachers-retirement-system.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.